BI 3034701
DrugBI 3034701
NCT Number: NCT07693231
Part 1:
To investigate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BI 3034701 in Japanese male and female participants with body mass index (BMI) ≥27.0 kg/m² or more following subcutaneous administration of multiple rising doses over 16 weeks.
Part 2:
To investigate safety, tolerability, and PK of BI 3034701 in Japanese male and female healthy participants with BMI ≥23.0 to <27.0 kg/m² following subcutaneous administration of multiple rising doses over 7 weeks.
Interested in participating?
Request Info18 year–64 year
All sexes
Interventional
Phase 1
Fukuoka Mirai Hospital, Fukuoka, Fukuoka, Japan
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
BI 3034701
Placebo
Time frame: Part 1: up to Week 19, Part 2: up to Week 10
Expressed as the percentage of trial participants treated with investigational drug who experience such an event
Time frame: Part 1: up to Week 17, Part 2: up to Week 8
Time frame: Part 1: up to Week 19, Part 2: up to Week 10
Time frame: Part 1: at Baseline and at Week 16
Contact information is provided by the study sponsor or research team.
Boehringer Ingelheim
Industry
A Phase I, Single-blinded, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 3034701 in Japanese Male and Female Participants With Obesity/Overweight and Otherwise Healthy (Part 1) and Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 3034701 in Japanese Male and Female Healthy Volunteers (Part 2)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01399385
Arterial Occlusive Diseases, Arteriosclerosis
Bethesda, Maryland, United States
View Trial DetailsNCT05219799
Aneurysm, Body Weight
Columbia, Missouri, United States
View Trial DetailsNCT07407348
Body Weight, Healthy
Nottingham, United Kingdom
View Trial DetailsNCT06592261
Body Weight, Diabetes Mellitus
New York, United States
View Trial Details